Pharming Group N.V. reported Q3 2025 revenue of $97.3 million, a 30 % year‑over‑year increase that exceeded the consensus estimate of $91.7 million by $5.6 million. GAAP earnings per share were $0.01, matching the consensus estimate of $0.05 and falling short of the $0.06 estimate that some analysts had projected. The quarter’s top line growth was driven by a 29 % rise in RUCONEST revenue to $82.2 million and a 35 % rise in Joenja revenue to $15.1 million, reflecting strong demand in both the hereditary angioedema and activated phosphoinositide 3‑kinase D (APDS) markets.
Continue reading for full analysis...